Meet OracleBio at ASCO 2016, Chicago, June 4th – 6th – Booth 14114

| June 1, 2016

oraclebioOracleBio, a leading provider of high quality precision histopathology image analysis services to support Pharmaceutical R&D, companion diagnostics development, pathology review and biomarker research, will be exhibiting at the American Society of Clinical Oncology (ASCO) congress 2016 in Chicago from June 4th – 6th.

OracleBio combines over 75 years of Pharma R&D experience with expertise in the principles and application of histology image analysis within Oncology research, with an overall focus on the delivery of assured, robust data in support of R&D processes. Our services can help deliver detailed exploratory biomarker data as part of your clinical oncology trial, confirm the Mechanism of Action of your therapy within the tumor microenvironment and improve translation and decision making between pre-clinical and clinical studies.

Recent advances in immune/inflammatory cell spatial context analysis are currently being implemented as part of our analysis capabilities, including measures defining tumor regions and interfaces and cell-cell interactions, to assist in relating pathology changes to mechanisms of action for immunotherapies.

Meet with Chief Scientific Officer Lorcan Sherry and Clinical Operations Manager Alison Bigley at Exhibitor booth 14114 in the Oncology Professionals Hall to discuss how OracleBio can support quantification of histological end points from your clinical oncology studies. To pre-arrange a meeting, contact us at, or meet with us directly at the booth during the congress.

Source: OracleBio

Tags: , , , , ,

Category: Advocacy, Anatomic Pathology, Business, Clinical Laboratories, Conferences, Current Affairs, Device Manufacturers, Digital Pathology News, Education, File format, Histology, Image Analysis, Informatics, International, Laboratory Informatics, Laboratory Management & Operations, Marketing, Medical Research, Pathology News, Science, Training, Vendor products, Web/Tech, Whole slide

Comments are closed.